ARWR - Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies | Benzinga

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were trading higher by 6% to $27.54 during Monday’s session after the company announced that it presented preclinical data on ARO-INHBE at the American Diabetes Association 84th Scientific Sessions.

The data showed ARO-INHBE significantly silenced the INHBE gene in the liver, potentially leading to reduced body weight gain, fat mass loss and preservation of lean mass. Arrowhead plans to seek regulatory clearance in late 2024 to begin clinical trials.

In obese and diabetic mice, INHBE siRNA reduced INHBE mRNA expression by 95%, body weight by 19% and fat mass by 26%, while preserving lean mass. Additionally, ...

ARWR) Stock Is Seeing Blue Skies>Full story available on Benzinga.com